Challenges in clinical trial design for HIV-1 cure research
N Eyal, DR Kuritzkes - The Lancet, 2013 - thelancet.com
N Eyal, DR Kuritzkes
The Lancet, 2013•thelancet.com2 Groopman JE, Mayer KH, Sarngadharan M, et al. Seroepidemiology of HTLV-III among
homosexual men with the acquired immune deficiency syndrome, generalized
lymphadenopathy, and asymptomatic controls in Boston. Ann Intern Med 1985; 102: 334–
37. 3 Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention,
and treatment. Lancet 2006; 368: 489–504. 4 Sullivan A. When plagues end. New York
Times Dec 1, 1996. http://www. nytimes. com/1996/12/01/magazine/l-when-plagues-end …
homosexual men with the acquired immune deficiency syndrome, generalized
lymphadenopathy, and asymptomatic controls in Boston. Ann Intern Med 1985; 102: 334–
37. 3 Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention,
and treatment. Lancet 2006; 368: 489–504. 4 Sullivan A. When plagues end. New York
Times Dec 1, 1996. http://www. nytimes. com/1996/12/01/magazine/l-when-plagues-end …
2 Groopman JE, Mayer KH, Sarngadharan M, et al. Seroepidemiology of HTLV-III among homosexual men with the acquired immune deficiency syndrome, generalized lymphadenopathy, and asymptomatic controls in Boston. Ann Intern Med 1985; 102: 334–37. 3 Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368: 489–504. 4 Sullivan A. When plagues end. New York Times Dec 1, 1996. http://www. nytimes. com/1996/12/01/magazine/l-when-plagues-end-490881. html (accessed Sept 25, 2013).
thelancet.com